New Zealand markets closed

ImmunoPrecise Antibodies Ltd. (IPA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
3.8400-0.0200 (-0.52%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 92.16M
Enterprise value 68.72M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)5.20
Price/book (mrq)2.54
Enterprise value/revenue 3.62
Enterprise value/EBITDA -6.11

Trading information

Stock price history

Beta (5Y monthly) -0.23
52-week change 3-37.36%
S&P500 52-week change 3-11.93%
52-week high 316.4700
52-week low 33.5100
50-day moving average 34.8686
200-day moving average 35.4304

Share statistics

Avg vol (3-month) 322.25k
Avg vol (10-day) 315.08k
Shares outstanding 523.54M
Implied shares outstanding 6N/A
Float 816.17M
% held by insiders 15.91%
% held by institutions 15.34%
Shares short (14 Jun 2022) 4231.72k
Short ratio (14 Jun 2022) 414.43
Short % of float (14 Jun 2022) 4N/A
Short % of shares outstanding (14 Jun 2022) 40.98%
Shares short (prior month 12 May 2022) 4226.8k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 322 Nov 2020
Ex-dividend date 4N/A
Last split factor 21:5
Last split date 322 Nov 2020

Financial highlights

Currency in CAD.

Fiscal year

Fiscal year ends 29 Apr 2021
Most-recent quarter (mrq)30 Jan 2022


Profit margin -89.98%
Operating margin (ttm)-78.59%

Management effectiveness

Return on assets (ttm)-18.66%
Return on equity (ttm)-42.77%

Income statement

Revenue (ttm)19M
Revenue per share (ttm)0.99
Quarterly revenue growth (yoy)6.60%
Gross profit (ttm)11.4M
EBITDA -14.06M
Net income avi to common (ttm)-17.1M
Diluted EPS (ttm)-0.6850
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)32.99M
Total cash per share (mrq)1.7
Total debt (mrq)2.81M
Total debt/equity (mrq)5.90
Current ratio (mrq)5.68
Book value per share (mrq)2.45

Cash flow statement

Operating cash flow (ttm)-8.87M
Levered free cash flow (ttm)-4.02M